Prevention of Fertility due to Chemotherapy-Induced Ovarian Failure: Role of Therapeutic Antioxidants

Basit Öğe Kaydı
dc.authorscopusid55193447200
dc.authorscopusid58293385100
dc.authorscopusid57344078500
dc.authorscopusid55274353300
dc.contributor.authorMelekoglu R.
dc.contributor.authorDogan U.K.
dc.contributor.authorCelik N.Z.
dc.contributor.authorYilmaz E.
dc.date.accessioned2024-08-04T20:03:54Z
dc.date.available2024-08-04T20:03:54Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAdvancements in chemotherapy treatments are leading to increased survival rates for cancer sufferers. Advances in anticancer therapy have contributed to higher survival rates, but ovarian failure that leads to infertility is one of the long-term adverse effects due to primordial follicle loss caused by gonadotoxic chemotherapy. Therefore, prevention of premature ovarian failure and protection of the ovarian follicle pool has gained increasing attention to improve the quality of life of female cancer patients receiving chemotherapy. A non-invasive medical approach (including administration of antioxidant therapy to conventional chemotherapy regimens) to prevent chemotherapy-induced ovarian damage may be preferred, although there are successful invasive fertility preservation options. Most of the chemotherapeutic agents act by producing free radicals that cause cellular damage and necrosis of malignant cells as part of their mode of action in cancer treatment. Despite nearly three decades of research that sought to determine the effectiveness and safety of dietary antioxidant supplementation while undergoing conventional chemotherapy, some controversy remains about efficacy and safety. This claim has been backed up by numerous clinical trials which have demonstrated that certain antioxidants help to restore the body’s natural antioxidants, which are often depleted after chemotherapy treatment, and reduce side effects of cytotoxic agents, including prevention of chemotherapy-induced ovarian failure as well as increase in overall survival of patients receiving chemotherapy. Further randomized controlled clinical researches should be designed to evaluate the use of a specific combination of antioxidants in chemotherapy and determine optimal doses of antioxidants for specific cancer setting to prevent chemotherapy-induced ovarian failure. © Springer Nature Singapore Pte Ltd. 2022.en_US
dc.identifier.doi10.1007/978-981-16-5422-0_10
dc.identifier.endpage171en_US
dc.identifier.isbn9789811654220
dc.identifier.isbn9789811654213
dc.identifier.scopus2-s2.0-85160460764en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage153en_US
dc.identifier.urihttps://doi.org/10.1007/978-981-16-5422-0_10
dc.identifier.urihttps://hdl.handle.net/11616/92182
dc.identifier.volume1en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Singaporeen_US
dc.relation.ispartofHandbook of Oxidative Stress in Cancer: Therapeutic Aspects: Volume 1en_US
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntioxidantsen_US
dc.subjectChemotherapyen_US
dc.subjectCisplatinen_US
dc.subjectCyclophosphamideen_US
dc.subjectInfertilityen_US
dc.subjectOvaryen_US
dc.subjectOxidative stressen_US
dc.subjectPremature ovarian failureen_US
dc.titlePrevention of Fertility due to Chemotherapy-Induced Ovarian Failure: Role of Therapeutic Antioxidantsen_US
dc.typeBook Chapteren_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu